Sinovac Pharmaceuticals Aims for Dual A+H Listing, Valued at 6.2 Billion USD, Yet Innovation Potential May Be Limited

In the past two years, the trend of "A+H" listings has surged again. To date, more than 100 A-share companies are at various stages of going public in Hong Kong. (Refer to the list of A+H dual-listed companies at the end of this article.) Among these, there are no shortage of biopharmaceutical firms; Hengrui Pharma has already successfully listed on the Hong Kong stock exchange, while Baili Tianhe remains stuck at the final stage of its listing process. Additionally, Sinovac Biotech, Maiwei Bio, Changchun High-Tech, Beta Pharma, Yuekang Pharma, Zelgen Biopharma, SinoPharm Nova, Yifang Bio, Oulin Bio, and Bai Bioscience have all submitted their applications to the Hong Kong Stock Exchange. According to Gelonghui, Sinovac Biotech Co., Ltd. (referred to as: Sinovac Pharma) has submitted its application to the Hong Kong Stock Exchange.

Gelonghui FinanceFeb 11 17:58

Express News | A-Share Market Review: Shanghai Composite Index Narrowly Rises by 0.13%, Gold Concept Stocks See Comprehensive Correction

BreakingsFeb 10 15:15

A cluster of STAR Market companies have been listed on the 'China Top 500 Enterprises' ranking, with Shanghai leading in growth rate.

①The Hurun Research Institute released the "Hurun China 500 Strong 2025" list, showcasing an upward trend in both the scale and quality of China's private economy. ②The list indicates that companies in hard technology sectors such as semiconductors, biomedicine, and new energy have seen increases in both numbers and market value. Shanghai has become the city with the fastest growth in the number of listed companies nationwide, with a significant concentration of STAR Market enterprises appearing on the list.

cls.cnFeb 5 22:30

The Hurun China 500 Strong 2025 list has been released! The total value of the companies reached 77 trillion yuan, increasing by nearly 40%.

On February 5, the Hurun Research Institute released the '2025 Hurun China 500 Strong,' listing the top 500 non-state-owned enterprises in China.

Zhitong FinanceFeb 5 13:58

Baili Tianheng (688506.SH): Cumulative repurchase of 321,400 company shares

Gelonghui, February 3rd - Balie Tianhe (688506.SH) announced that as of January 31, 2026, the company had cumulatively repurchased 321,398 shares through the Shanghai Stock Exchange trading system via centralized bidding. These shares account for 0.08% of the company’s total equity. The highest price paid per share was RMB 345.24, and the lowest price was RMB 279.72 per share. The total amount of funds expended was RMB 99.8542 million (excluding stamp duty, transaction commissions, and other related fees).

Gelonghui FinanceFeb 3 17:34

Sichuan Bailitianheng Pharmaceutical Co., Ltd. – 2025 Annual Performance Forecast

SZSIJan 31 00:00 · Announcements